3D Cancer Model Development Services

Online Inquiry

Name *

Email *

Phone *

Services Or Products Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

AI-Powered Organ-on-Chip Platform

Alfa Cytology's AI-powered organ-on-chip platform integrates human-relevant microphysiological systems with image-based artificial intelligence. This technology enables predictive drug discovery while reducing animal model dependency. Fully customizable and end-to-end services support every stage, from tumor organoid generation and characterization to high-throughput screening and mechanistic analysis. Flexible partnership models deliver tailored solutions that align with specific research objectives, streamlining preclinical workflows and accelerating data-driven decisions.

Overview of the AI-Powered Organ-on-Chip Platform

This platform combines microfluidic engineering with advanced computational analytics to replicate human organ pathophysiology in vitro. Unlike conventional static cultures, the system supports dynamic perfusion, multicellular co-culture, and real-time imaging. AI-driven image analysis extracts multiplexed morphological and functional endpoints, enabling unbiased, high-content phenotyping. Key capabilities include:

Microfluidic Engineering

Channel designs allow spatial control of hydrogel and perfusion, enabling stable co-culture of multiple cell types and recapitulating paracrine signaling and cellular interactions similar to in vivo conditions.

Dynamic Perfusion

Continuous medium flow supplies nutrients and removes waste, mimicking blood circulation. This supports long‑term culture, real‑time monitoring, and higher physiological relevance than static systems.

AI‑Driven Analytics

Machine learning pipelines can be integrated to process morphological, secretory, and multi‑omics data from high‑content imaging. Unbiased pattern detection identifies subtle phenotypic responses and predicts drug efficacy or toxicity.

Multimodal Integration

Image‑based features are combined with transcriptomic, proteomic, and metabolic datasets. The resulting multiplexed profiles capture cellular heterogeneity and enable predictive modeling of drug responses.

Strengths and Limitations of Existing Preclinical Models

Traditional preclinical models often fail to predict human responses accurately, leading to late‑stage attrition and high development costs. Each model system presents a distinct trade‑off between biological relevance, throughput, cost, and turnaround time. The table below summarizes key advantages and limitations of commonly used platforms.

Model System	Advantages	Limitations
2D Cell System	High throughput; simple operation; suitable for mechanistic studies	Lacks organ‑specific microenvironment; immortalized cell lines have altered physiology; no vascular system; poor reproducibility; fails to predict drug sensitivity
PDX Mouse Model	Retains in vivo tumor characteristics; clinically predictive for certain agents	Long cycle (4-8 months); high cost due to animal housing; requires large tissue volumes; low engraftment rate for some tumor types; poor reproducibility across labs
3D Tumor Organoids	Preserves histologic and genetic features of parent tumors; higher throughput than PDX; lower cost; short turnaround (weeks); minimal tissue input	Semi‑physiological state; lacks vascularization and immune components; static culture limits nutrient/gas exchange; no real‑time monitoring of dynamic processes
Organoid Chip	Simulates in vivo microenvironment (flow, barriers, vascularization, immune co‑culture); dynamic culture enables real‑time imaging; high construction success rate; low sample volume	Requires specialized equipment and training; higher per‑unit cost than 2D or basic organoids

Advantages of Our AI-Powered Organ-on-Chip Platform

This technology redefines the speed and accuracy of drug assessment by replacing qualitative observation with high-throughput, quantitative intelligence. By achieving predictive accuracy levels up to 90%, the platform empowers researchers to de-risk assets earlier in the development cycle, saving years of iterative laboratory work and millions in R&D expenditure.

Predictive Accuracy

Tumor organoid-on-a-chip achieves>90% concordance with clinical responses, versus 50–65% for animal models. Physiological flow and multicellular architecture enable reliable go/no‑go decisions.

High Throughput & Scalability

Designed for pharmaceutical-scale screening, the platform enables the simultaneous testing of hundreds of chips, facilitating large-scale lead optimization without compromising biological complexity.

Reduced Timelines and Costs

Compresses preclinical development cycles from 18 months to just 1–4 months, drastically lowering the overhead costs associated with long-term animal studies and specialized facilities.

AI-Powered Image Analytics

Proprietary deep-learning pipelines provide rapid, unbiased quantification of 3D morphological changes and cellular responses, detecting subtle drug effects that manual analysis might overlook.

Flexible Configurations

Offers modular designs that adapt to specific research needs, from "off-the-shelf" tissue models to customized, multi-cellular environments tailored for unique disease mechanisms.

Early Risk Assessment

Identifies potential toxicities and safety liabilities during the initial stages of discovery, preventing costly late-stage failures and allowing for more informed candidate prioritization.

Applications of the AI-Powered Organ-on-Chip Platform

The versatility of this platform enables the simulation of complex biological processes across various therapeutic areas, providing researchers with granular insights into disease progression. This technology is applied across multiple stages of drug discovery and safety assessment, offering human‑relevant insights that complement or replace animal studies. Key application areas include:

Tumor‑on‑Chip Modeling: Tumor organoids are co‑cultured with immune cells (e.g., CAR‑T, checkpoint inhibitors) to evaluate immuno‑oncology drug candidates. Vascularized tumor chips assess drug penetration and angiogenesis.
Safety Pharmacology: Liver chips with primary human hepatocytes (multi‑donor) predict drug‑induced liver injury. Kidney and vascular chips detect nephrotoxicity and cardiovascular liabilities early, reducing late‑stage failures.
Vascular Dynamics: Endothelialized organ models recapitulate barrier function, shear stress, and transendothelial migration. These chips evaluate drug effects on vascular permeability, thrombosis risk, and extravasation.
Disease Microenvironment Simulation: Recreating extracellular matrix, mechanical forces, and cellular interactions (e.g., fibroblasts, endothelial cells) enables the study of fibrosis, metastasis, and inflammatory conditions not captured in static cultures.

Our Services

By leveraging a unique synergy of microfluidic precision and computational intelligence, Alfa Cytology delivers end-to-end services to accelerate the transition from bench to bedside. This expertise allows for the highly specialized preclinical drug research and development that meets the rigorous demands of global regulatory frameworks and pharmaceutical standards.

Customized Preclinical Research Solutions

Alfa Cytology's platform provides end‑to‑end, tailorable workflows that bridge target discovery through efficacy assessment. By combining organoids, microfluidic co‑culture, and AI‑powered multi‑omics analysis, we build models that mirror human pathophysiology. Each solution is co‑developed with the client's specific therapeutic area, stage of development, and regulatory requirements in mind. From a single assay design to full‑scale screening campaigns, the system adapts to the desired throughput, biological complexity, and readout modalities, enabling a truly customized approach to preclinical research.

Target Validation and Drug Discovery

Disease microenvironments on chip are recreated, including heterotypic cell‑cell interactions, extracellular matrix, and biomechanical forces. Phenotypic AI then detects subtle morphological changes, and when integrated with multi‑omics, identifies and validates novel drug targets with human relevance.

Drug Efficacy and Disease Modeling

Human‑relevant efficacy models include tumor‑on‑chip with immune co‑culture for immuno‑oncology, and vascularized chips for assessing drug penetration and anti‑angiogenic effects. Toxicity models (liver, kidney, vascular) enable concurrent efficacy‑safety profiling of lead candidates in an experimental batch.

Customized Therapy Development

Using unique organoids and matched immune or stromal components, we build customized chips that mirror an individual's disease landscape. This platform guides precision medicine by identifying optimal drug combinations and predicting resistance mechanisms before clinical administration.

Workflow of the AI‑Powered Organ‑on‑Chip Platform

Consultation & Study Design: Research objectives are reviewed to select appropriate organoid types, chip configurations, perfusion parameters, and endpoints. Throughput and complexity are matched to project timelines.
Sample Processing & Organoid Generation: Patient biopsies or commercial tissue sources are processed to generate tumor or healthy organoids under standardized conditions. Quality control includes viability, morphology, and marker expression.
Chip Fabrication & Perfusion Setup: Microfluidic chips are loaded with extracellular matrix, organoids, and supporting cell types (e.g., endothelium, immune cells). Automated perfusion systems maintain dynamic flow and continuous medium exchange.
Drug Treatment & Dynamic Monitoring: Test compounds are introduced at defined concentrations and schedules. Real‑time sensors or periodic imaging track barrier integrity, cell viability, and morphological changes throughout the culture period.
High‑Content Imaging: Endpoint or time‑lapse imaging is performed using automated confocal microscopy. Multiple staining panels capture subcellular structures, protein localization, and cell‑cell interactions in 3D.
AI Data Analysis & Reporting: Machine learning pipelines extract morphological and multiplexed features from imaging data. Integrated multi‑omics (where applicable) generates predictive models of efficacy, toxicity, or resistance. Final reports include quantified metrics, statistical comparisons, and interpretation for go/no‑go decisions.

Available Organ‑on‑Chip Model Types

Leveraging the dual‑channel chip, three‑channel chip, and integrated perfusion system, our platform supports a broad range of organ‑on‑chip models. These are organized into two main categories: Efficacy Models for therapeutic evaluation and Toxicity Models for safety assessment. Each model can be deployed as an off‑the‑shelf validated system or customized with patient‑derived materials.

Efficacy Models

Tumor‑on‑Chip: Patient tumor organoids cultured under flow with optional stromal or immune co‑culture, supporting monotherapy, combination, and immuno‑oncology screening.
Immune Co‑Culture Chip: Tumor or healthy organoids co‑cultured with autologous or allogeneic immune cells (T cells, NK cells, macrophages, or PBMCs) under dynamic perfusion to evaluate checkpoint inhibitors, bispecific antibodies, and cell therapies.
Vascularized Chip: Endothelialized organ models for assessing drug penetration and angiogenesis.

Toxicity Models

Liver Toxicity Chip: Primary hepatocytes with Kupffer and stellate cells under flow to predict DILI, steatosis, cholestasis, and metabolic liabilities.
Kidney Chip: Renal proximal tubule or podocyte models under fluid shear stress for nephrotoxicity prediction of small molecules and biologics.
Healthy Tissue Chip: Normal organoids (colon, liver, kidney, lung, cardiac) for off‑target toxicity screening and therapeutic index calculation.

Why Choose Us?

Physiological Fidelity: By combining 3D organoids with dynamic fluidic forces, the platform creates a model that mimics the human internal environment with higher fidelity than other in vitro systems.
End-to-end Integrated Capabilities: From tumor organoid generation and characterization to AI-powered image analysis and multi-omics profiling, all steps operate within a single continuous workflow.
Scalability and Automation: High-throughput screening systems have demonstrated time and cost savings across multiple disease models, with technical validation completed in multi-center studies.
Rigorous Methodological Validation: Every study is designed with validation in mind, providing the robust data quality required for regulatory submissions.

Contact Us

Alfa Cytology's AI-powered organ-on-chip platform closes the gap between preclinical models and human pathophysiology through engineering innovation, automated high-content imaging, and computational analytics. Customizable end-to-end services, from cancer organoid development to predictive drug screening, empower faster, more accurate research decisions. Contact our team to discuss specific research needs or to initiate a collaborative project.

Reference

Kretzschmar, Kai. "Cancer research using organoid technology." Journal of molecular medicine (Berlin, Germany) 99.4 (2021): 501-515.

For research use only.